Celltrion Inc
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
375 / 1361
Position in country
1679 / 2780
Return on Assets, %
8.6
-40.3
Net income margin, %
0.1
-180
EBITDA margin, %
24
-168.2
Debt to Equity, %
11.1
3.2
Intangible assets and goodwill, %
66.9
0.2
Revenue CAGR 3Y, %
5.5
12.5
Total Equity change 1Y, %
299.6
-9
Revenue Y, % chg
-6.1
0
P/E
48.4
31
P/BV
2.2
1.8
P/S
18.2
10.3
EV/S
19
7.5
EV/EBITDA
45.9
-1.6
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
24.9
131.1
Forward P/E
38.8
21.4
Dividend Yield, %
0.2
1.1
Forward Dividend Yield, %
0
0.1
Expected dividend per share
0.3
0
Payout Ratio, %
19.3
0
Dividend Ex Date
2023-12-27
Competitors
Ranks
-
PharmaResearch Co Ltd
00%
-
Hugel Inc
00%
-
Amgen Inc
00%
-
Celltrion Inc
00%
-
Seegene Inc
00%
-
Alteogen Inc
00%
-
GC Biopharma Corp
00%
-
ABL Bio Inc
00%
-
AbbVie Inc
00%
-
SK Bioscience Co Ltd
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Korea; Republic (S. Korea)
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
29062.4
Ticker
068270.KS
ISIN
KR7068270008
IPO date
2005-07-19
Availability on Russian exchanges
No
Reporting for
2024-03-18
Date fact. publication of reports
2023-12-31
Company Description
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: